Mirvetuximab soravtansine
- Generic Name
- Mirvetuximab soravtansine
- Brand Names
- Elahere
- Drug Type
- Biotech
- CAS Number
- 1453084-37-1
- Unique Ingredient Identifier
- 98DE7VN88D
- Background
Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide linker to the genotoxic compound DM4 (also known as soravtansine or ravtansine). DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1.
The antibody component of mirvetuximab soravtansine-gynx binds to FRα, a receptor overexpressed on the surface of epithelial tumor cells, characteristic of ovarian, endometrial, triple-negative breast and non-small-cell lung cancers. After an ADC/receptor complex is formed, mirvetuximab soravtansine-gynx is internalized, and DM4 is released inside the cell. DM4 leads to cell-cycle arrest and apoptosis and is also able to diffuse into neighboring cells and induce further cell death.
On November 2022, the FDA granted accelerated approval to mirvetuximab soravtansine-gynx for the treatment of adult patients with FRα–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1-3 prior systemic treatment regimens. This decision was supported by findings from the phase 3 SORAYA trial (NCT04296890).
- Indication
Mirvetuximab soravtansine is indicated for the treatment of adult patients with folate receptor alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Patients are selected for therapy based on an FDA-approved test.
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
- Associated Conditions
- Platinum-resistant Epithelial Ovarian Cancer, Platinum Resistant Primary Peritoneal Cancer, Platinum drug resistant Fallopian tube cancer
Innovent Biologics to Present Breakthrough Clinical Data for IBI363 PD-1/IL-2 Bispecific Antibody at ASCO 2025
• Innovent Biologics will showcase seven oral presentations at ASCO 2025, featuring breakthrough clinical data for its novel PD-1/IL-2α-bias bispecific antibody IBI363 in melanoma, colorectal cancer, and non-small cell lung cancer.
• IBI343, Innovent's anti-CLDN18.2 antibody-drug conjugate, secured an oral presentation slot for its Phase 1b data in pancreatic cancer, demonstrating promising potential in this difficult-to-treat malignancy.
• The company's robust pipeline of bispecific antibodies and ADCs highlights Innovent's growing position as a leader in the "IO+ADC" space, with multiple candidates advancing toward pivotal-stage development.
Regeneron Expands Biologic Manufacturing Capacity with $3 Billion FUJIFILM Partnership
• Regeneron Pharmaceuticals has announced a $3 billion manufacturing agreement with FUJIFILM Diosynth Biotechnologies in North Carolina, nearly doubling its U.S. large-scale manufacturing capacity for biologic medicines.
• The ten-year partnership is part of Regeneron's broader $7 billion investment strategy across New York and North Carolina, including a $3.6 billion expansion of its Tarrytown campus creating 1,000 high-skill jobs.
• The expansion reflects growing demand for Regeneron's biologic medicines and reinforces the company's commitment to U.S.-based manufacturing, having added over 7,000 jobs in the past five years.
Orca Bio's Phase III Precision-T Study Shows Promise for Novel T-Cell Immunotherapy in Blood Cancers
• Orca Bio announced positive results from its pivotal Phase III Precision-T study evaluating Orca-T, an investigational allogeneic T-cell immunotherapy for various blood cancers including AML, ALL, and high-risk MDS.
• The innovative therapy utilizes highly purified regulatory T-cells, hematopoietic stem cells, and conventional T-cells derived from matched donors' peripheral blood, representing a potential advancement in blood cancer treatment.
• The study's findings position Orca-T as a promising late-stage candidate in the cellular therapy landscape, potentially offering new options for patients with difficult-to-treat hematologic malignancies.
Evidence-Based Survivorship Care Programs Enhance Quality of Life for Cancer Patients
• Survivorship care addresses the comprehensive needs of cancer patients after primary treatment, with approximately 20 million cancer survivors in the U.S. expected to reach 26-27 million by 2040.
• Evidence-based survivorship programs that address emotional, physical, and practical needs have been shown to reduce emergency department visits and rehospitalizations while improving quality of life outcomes.
• Multidisciplinary approaches including psychological support, wellness clinics, and supportive therapies are essential components of comprehensive cancer care, particularly as the aging population faces increased cancer rates and treatment complexities.
Luveltamab Tazevibulin Shows Promising Results in Platinum-Resistant Ovarian Cancer with Low to High FRα Expression
• Luveltamab tazevibulin demonstrated a 32% overall response rate in platinum-resistant ovarian cancer patients with FRα expression ≥25%, showing similar efficacy in both low-medium and high expression subgroups.
• The antibody-drug conjugate achieved a remarkable 96% disease control rate when administered at 5.2 mg/kg with G-CSF prophylaxis for the first two cycles, then 4.3 mg/kg in subsequent cycles.
• Common side effects included arthralgia, nausea, and neutropenia, with researchers selecting the optimized dose regimen for the ongoing phase 3 portion of the REFRΑME-O1 trial.
Verastem Oncology to Present New LGSOC Treatment Data at SGO 2025 Annual Meeting
• Verastem Oncology will present additional analyses from the Phase 2 RAMP 201 trial evaluating avutometinib plus defactinib in recurrent low-grade serous ovarian cancer at SGO 2025, building on their FDA Priority Review submission.
• The presentations include new subgroup analyses by KRAS mutational status, supporting the company's ongoing efforts to advance treatment options for RAS/MAPK pathway-driven cancers.
• The company's NDA for the avutometinib-defactinib combination therapy has received Priority Review from the FDA with a PDUFA date of June 30, 2025, for KRAS mutant LGSOC patients.
EPCORE NHL-2 Trial Shows Promise Combining Chemotherapy and Immunotherapy for DLBCL
• A phase Ib/II clinical trial led by Mount Sinai researchers demonstrates successful outcomes in combining chemotherapy with immunotherapy for diffuse large B-cell lymphoma treatment.
• The groundbreaking research, published in Blood journal, was conducted under the leadership of Dr. Joshua Brody, director of the Lymphoma Immunotherapy Program at the Tisch Cancer Institute.
• The study represents a significant advancement in lymphoma treatment, supported by the Leukemia & Lymphoma Society's research initiatives, which have invested over $600 million in hematologic oncology research.
Clinical Trial Industry Faces Complex Challenges in 2025: Adaptive Designs, Political Shifts, and Diversity Requirements
• Clinical trials are becoming increasingly complex and expensive as they target smaller patient populations and face stricter regulations, driving the need for smarter and more efficient trial designs.
• Political changes, including Trump's presidency, could lead to significant regulatory shifts in the clinical trial landscape, potentially affecting approval pathways and oversight mechanisms.
• New legislation like the Inflation Reduction Act is expected to impact trial initiations and drug development, while diversity guidelines from WHO, FDA, and EMA present both opportunities and challenges for patient recruitment.
AbbVie's Telisotuzumab Vedotin Shows Promise in c-Met Overexpressing NSCLC
• AbbVie's telisotuzumab vedotin (Teliso-V) demonstrated a 35% overall response rate in patients with high c-Met expression in the LUMINOSITY trial.
• The FDA granted breakthrough therapy designation to Teliso-V, highlighting its potential to significantly improve outcomes in NSCLC patients.
• A phase 3 trial (TeliMET-NSCLC-01) is underway, comparing Teliso-V to docetaxel in c-Met-positive, non-squamous NSCLC patients.
• Teliso-V targets c-Met, a protein involved in cancer progression and resistance to therapies like EGFR inhibitors, offering a novel approach.
ImmunoGen's ELAHERE Receives Accelerated FDA Approval for Ovarian Cancer Treatment
ImmunoGen, Inc. has achieved accelerated FDA approval for its ovarian cancer drug ELAHERE, targeting patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. This marks a significant advancement in treatment options for patients with limited alternatives.
Corcept Therapeutics Submits New Drug Application for Relacorilant to Treat Cushing's Syndrome
• Corcept Therapeutics has submitted a New Drug Application to the FDA for relacorilant, a selective cortisol modulator designed to treat patients with endogenous hypercortisolism (Cushing's syndrome).
• The application is supported by positive results from multiple clinical trials, including the pivotal GRACE trial, Phase 3 GRADIENT study, and long-term extension studies, demonstrating improvements in various symptoms with an acceptable safety profile.
• Relacorilant showed no instances of serious adverse events common in current treatments, such as drug-induced adrenal insufficiency, hypokalemia, or QT prolongation, positioning it as a potential new standard of care.
Mirvetuximab Soravtansine Gains Global Approvals for FRα-Positive Platinum-Resistant Ovarian Cancer
• Mirvetuximab soravtansine receives European Commission approval for treating FRα-positive, platinum-resistant ovarian cancer after 1-3 prior systemic treatments.
• The approval was based on the MIRASOL trial, demonstrating a 35% reduction in disease progression or death risk and a 33% reduction in mortality compared to chemotherapy.
• The FDA granted full approval in March 2024, reinforcing mirvetuximab soravtansine's efficacy and superiority over standard care options for advanced ovarian cancer.
• Early FRα testing and specialist management of ocular toxicities are crucial for maximizing the efficacy and maintaining the quality of life for patients on mirvetuximab soravtansine.
EU Approves AbbVie's Elahere for Platinum-Resistant Ovarian Cancer
• AbbVie's Elahere (mirvetuximab soravtansine) receives EU approval for folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer, marking a significant advancement in treatment options.
• Elahere is the first antibody-drug conjugate (ADC) approved in the EU for this indication, demonstrating improved overall survival compared to chemotherapy in the MIRASOL trial.
• The approval addresses a critical unmet need, as it ends a decade-long gap in new treatments for platinum-resistant ovarian cancer in the EU, offering hope for improved outcomes.
• This approval, based on the MIRASOL trial, showed a 33% reduction in the risk of death and a 35% improvement in progression-free survival compared to chemotherapy.
AbbVie to Acquire Cerevel, Novartis' Fabhalta Approved, and Other Pharma Updates
• AbbVie is set to acquire Cerevel Therapeutics for $8.7 billion, bolstering its neuroscience pipeline with candidates targeting schizophrenia, Parkinson's disease, and mood disorders.
• The FDA has approved Novartis' Fabhalta (iptacopan), the first oral monotherapy for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder.
• Pfizer halted Phase III development of its twice-daily obesity drug, danuglipron, due to significant gastrointestinal side effects observed in Phase II trials.
• Biogen and Eisai received full FDA approval for Leqembi, an Alzheimer's disease drug shown to slow cognitive decline, expanding Medicare coverage.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath